Skip to main content
. 2017 Oct 16;9(12):1629–1645. doi: 10.15252/emmm.201607445

Figure 8. Combining macrophage depletion with chemotherapy increases survival of glioma‐bearing mice.

Figure 8

  1. Experimental design for the survival trial: 8‐week‐old wild‐type mice were injected with GL261 cells to induce glioma formation and were assigned randomly to vehicle (n = 6), anti‐CSF1 monoclonal antibody treatment (0.5 mg; n = 6), temozolomide treatment (40 mg/kg; n = 6), or temozolomide and anti‐CSF1 mAb combination treatment (n = 6). Mice were weighed once daily until they developed symptoms or reached the trial endpoint.
  2. Survival curves of the mice described in (A). Combination therapy is significantly more efficient than chemotherapy alone. (n = 6 mice per group).
  3. phospho‐H2AX and Glut1 immunohistochemistry on 3‐week growth glioma in wild‐type mice treated as described in (A).
  4. Anti‐CSF1 antibody in combination with temozolomide chemotherapeutic agent induces a wider tumor cell death efficiency with a significant decrease of blood vessel caliber (D) and an increase in caspase3‐positive tumor cells (E) (50‐μm depth stack) (n = 6 mice per group).
Data information: Statistical analysis: (B) Multiple comparisons Mantel–Cox log‐rank; (D, E) one‐way ANOVA followed by multiple comparisons Tukey's test. Error bars: mean ± SD. Scale bar: (C) 300 μm.